Canlitinib

This letter aims to provide a forward-looking analysis of the recent preclinical study by Ou et al. (Angiogenesis, 2025) on the efficacy of the multi-kinase inhibitor KC1036 in Ewing sarcoma (ES).We conducted a critical appraisal of the reported data, focusing on the dual anti-angiogenic and direct anti-tumor mechanisms of KC1036. The analysis is contextualized within the current understanding of ES pathogenesis and treatment resistance.The original study compellingly demonstrates that KC1036, by concurrently inhibiting VEGFR and FGFR signaling, effectively suppresses ES growth. While these findings are promising, they raise pivotal questions for future investigation. Key considerations include the precise mechanistic interplay between KC1036 and the EWSR1-FLI1 oncogenic driver, the potential evolution of resistance despite multi-targeted inhibition, and the critical assessment of the agent's therapeutic index.KC1036 represents a rational and potent therapeutic candidate for ES. The primary challenges ahead lie in delineating its molecular mechanisms of action beyond angiogenesis, prospectively defining resistance pathways to guide combination therapies, and rigorously evaluating its safety profile to ensure successful clinical translation. This letter outlines these priorities to stimulate further research.